Literature DB >> 29798907

Targeted Therapies for Brain Tumors: Will They Ever Deliver?

Michael A Vogelbaum1.   

Abstract

The strategy of using biologically targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood-brain barrier on the ability of a therapeutic to reach its target(s). Clin Cancer Res; 24(16); 3790-1. ©2018 AACRSee related article by Sanai et al., p. 3820. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29798907     DOI： 10.1158/1078-0432.CCR-18-0855

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Therapeutic Options in Neuro-Oncology.

Authors:  Mariana Afonso; Maria Alexandra Brito
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis.

Authors:  Hui Yang; Xiaocen Liu; Xiaolong Zhu; Xueqin Li; Lan Jiang; Min Zhong; Mengying Zhang; Tianbing Chen; Mingzhe Ma; Xiuming Liang; Kun Lv
Journal:  JCI Insight       Date:  2021-12-22

Review 3.  Evolving Insights Into the Biological Function and Clinical Significance of Long Noncoding RNA in Glioblastoma.

Authors:  Kun Liu; Hong Chen; Yuanyuan Wang; Liping Jiang; Yi Li
Journal:  Front Cell Dev Biol       Date:  2022-04-21

Review 4.  Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment.

Authors:  Jie Qin; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

5.  Role of linc00174/miR-138-5p (miR-150-5p)/FOSL2 Feedback Loop on Regulating the Blood-Tumor Barrier Permeability.

Authors:  Jizhe Guo; Shuyuan Shen; Xiaobai Liu; Xuelei Ruan; Jian Zheng; Yunhui Liu; Libo Liu; Jun Ma; Teng Ma; Lianqi Shao; Di Wang; Chunqing Yang; Yixue Xue
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-09       Impact factor: 8.886
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.